Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks

Page 4 of 15

12. Pharvaris N.V. (NASDAQ:PHVS)

Number of Hedge Fund Holders: 15

Viking Global’s Stake: $67.7 million 

Pharvaris N.V. (NASDAQ:PHVS) is a late-stage biopharma company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks. The following factors underscore why the company is a solid investment opportunity. First of all, in pharmaceuticals, increased R&D spending can lead to future innovation, growth, and competitive advantages, and the company’s R&D expenses have increased from €18.5 million to €25.8 million, indicating that it is investing more in developing new products or technologies. Secondly, the company has also planned the initiation of CHAPTER-3, the pivotal Phase 3 study of deucrictibant extended-release tablets for the prophylactic treatment of HAE. Additionally, it has also announced its intention to pursue clinical development of deucrictibant in a newly named indication, acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), and presented a robust data set highlighting the differentiating characteristics of deucrictibant.

Page 4 of 15